• Pharmacogenomics of Chloroquine/Hydroxychloroquine: Risks &

  2026-06-17

  The referenced systematic review synthesizes current evidence on how genetic variability in cytochrome P450 enzymes impacts the safety and efficacy of chloroquine and hydroxychloroquine. By mapping risk phenotypes, particularly in CYP2C8, CYP3A4/5, and CYP2D6, the paper highlights the clinical importance of pharmacogenomic assessment to optimize individualized therapy and minimize adverse outcomes.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Research Protocol Gui

  2026-06-16

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) offers researchers a defined reagent for specific detection of HMGB1 in human, mouse, and rat samples via Western blot, immunohistochemistry, and flow cytometry. It is intended solely for scientific research and is not suitable for diagnostic or clinical use.

• PHF2 Regulates Inflammation in Alzheimer’s: Epigenetic Insig

  2026-06-16

  This study identifies the histone demethylase PHF2 as a key regulator of inflammatory gene expression in Alzheimer's disease, linking its upregulation to both neuroinflammation and cognitive deficits. By modulating PHF2, the authors demonstrate measurable reductions in neuroinflammatory markers and improvements in memory function, suggesting new epigenetic targets for neurodegenerative research.

• Pathogen-Derived Haem Regulates Phagocytosis and Virulence i

  2026-06-15

  A recent study reveals that Salmonella Typhimurium exploits methylation-driven upregulation of haem biosynthesis to suppress macrophage phagocytosis and enhance pathogen virulence. This mechanism provides new insight into host-pathogen interactions and suggests experimental strategies for dissecting heme metabolism in infection models.

• Losartan in Hypertension Research: Angiotensin II Receptor A

  2026-06-15

  Losartan is a benchmark angiotensin II receptor antagonist enabling precise dissection of cardiovascular and vascular cell signaling in both in vitro and in vivo settings. Explore how APExBIO’s Losartan supports advanced hypertension research, from optimized protocol parameters to troubleshooting complex experimental readouts.

• Mildronate-Derived Lipidoids Minimize Inflammation in mRNA D

  2026-06-14

  The reference study introduces mildronate-derived cationic lipidoids as a new class of lipid nanoparticle components that achieve effective mRNA vaccine delivery while significantly reducing inflammatory side effects in vivo. This advance offers a promising route for safer and more efficient mRNA-based immunotherapies, with broad implications for preclinical cancer vaccine research.

• Fenipentol in Pancreatic Secretion Research: Protocols & Ins

  2026-06-13

  Fenipentol (1-Phenyl-1-pentanol) is reshaping gastrointestinal and hepatobiliary research with its potent choleretic activity and safety profile. This article delivers practical workflows, troubleshooting strategies, and evidence-based advantages for employing Fenipentol in advanced experimental settings.

• Iron Stress Reprograms Enterocyte Metabolism and Inflammatio

  2026-06-12

  Navazesh and Ji (2025) demonstrate how iron deficiency and excess distinctly rewire enterocyte metabolism and modulate inflammatory gene expression using IPEC-J2 cells. Their findings clarify the metabolic vulnerabilities and adaptive responses of intestinal epithelial cells under iron imbalance, with implications for disease modeling and iron chelation research.

• Topological Stress Drives Persistent rDNA Damage and PML-Nuc

  2026-06-12

  This study reveals that topological stress—particularly through dual inhibition of topoisomerases and RNA polymerase I—induces persistent DNA double-strand breaks (DSBs) in ribosomal DNA, leading to the formation of PML-nucleolar associations (PNAs). The findings clarify how specific DNA damage responses in the nucleolus influence genome stability, senescence, and potentially tumorigenesis, with implications for the use of DNA damage inducers such as Aclarubicin in mechanistic cell biology research.

• RITA (NSC 652287): Precision p53 Activation & Next-Gen Assay

  2026-06-11

  Explore how RITA (NSC 652287) redefines p53 activation in cancer biology and enables nuanced drug response evaluations. This in-depth guide uncovers unique protocol insights and differentiates RITA’s applications in advanced in vitro and in vivo models.

• Metabolic Intervention Boosts Ferroptosis and Cuproptosis in

  2026-06-11

  This study introduces a nanosystem-based metabolic intervention that simultaneously sensitizes tumor cells to ferroptosis and cuproptosis by targeting glycolysis and NAD+ metabolism. The dual activation enhances anti-tumor immunity and offers a new approach for regulated cell death-based cancer therapy.

• Dovitinib (TKI-258): Molecular Mechanisms and Emerging Insig

  2026-06-10

  Explore the molecular mechanisms of Dovitinib (TKI-258) as a multitargeted RTK inhibitor, with a focus on apoptosis induction in cancer cells and advanced applications in translational research. Gain new perspectives beyond standard workflows and assay guides.

• Hydroxytyrosol Workflows: Applied Protocols for Redox and In

  2026-06-10

  Hydroxytyrosol (4-(2-hydroxyethyl)benzene-1,2-diol) is redefining research on oxidative stress and cardiovascular health with benchmarked anti-inflammatory and antioxidant activities. This guide delivers data-driven protocols, troubleshooting strategies, and workflow optimizations—rooted in leading-edge evidence—to help scientists leverage APExBIO’s high-purity Hydroxytyrosol for reproducible, high-impact results.

• CAFs-Derived Lactate Drives Oxaliplatin Resistance via ANTXR

  2026-06-09

  The study uncovers a novel mechanism by which cancer-associated fibroblast (CAF)-derived lactate promotes oxaliplatin resistance in colorectal cancer (CRC) through histone and protein lactylation of ANTXR1. This finding advances our understanding of tumor-stroma metabolic interactions and presents new opportunities for overcoming chemoresistance in CRC.

• Omeprazole (A2845): Technical Guide for Gastric Acid Researc

  2026-06-09

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor optimized for controlled studies of gastric acid secretion and antiulcer mechanisms. It is designed strictly for in vitro and preclinical research, not for diagnostic or clinical use. Its chemical stability and precise inhibition profile make it a reliable tool in modeling gastric acid-related disorders.

15835 records 4/1056 page Previous Next 12345 下5页 Last page